Amgen's AMGN stock hit a fresh 52-week high of $440.51 on Aug. 21, 2026, before closing the session at $439.33. The stock has gained 16.8% over the past month, mainly driven by strong second-quarter results and increased guidance. Amgen beat estimates for both earnings and revenues in the second quarter and raised its financial outlook for 2026 for the second time this year. The company's key growth drivers, which represent almost 70% of total product sales, rose 24% year over year in the first quarter and 26% in the second quarter. However, Amgen faces significant biosimilar pressure on its denosumab franchise, with Prolia sales declining 32% and Xgeva declining 34% in the second quarter. The Zacks Consensus Estimate for earnings has risen from $22.29 to $22.92 per share for 2026 over the past 30 days.
Amgen IncStrong Q2 results and raised guidance drove stock to 52-week high.
Eli Lilly and Company
Novo Nordisk A/S
Affiliated Managers Group, Inc.